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ABSTRACT
Background: Chronic obstructive pulmonary disease
(COPD) is often associated with other chronic diseases.
These patients are often admitted to hospital based
rehabilitation programmes.
Objectives: To determine the prevalence of chronic
comorbidities in patients with COPD undergoing pulmon-
ary rehabilitation and to assess their influence on
outcome.
Design: Observational retrospective cohort study.
Setting: A single rehabilitation centre.
Patients: 2962 inpatients and outpatients with COPD
(73% male, aged 71 (SD 8) years, forced expiratory
volume in 1 s (FEV1) 49.3 (SD 14.8)% of predicted),
graded 0, 1 or >2 according to the comorbidity
categories and included in a pulmonary rehabilitation
programme.
Measurements: The authors analysed the number of
self-reported comorbidities and recorded the Charlson
Index. They then calculated the percentage of patients
with a predefined positive response to pulmonary
rehabilitation (minimum clinically important difference
(MCID)), as measured by improvement in exercise
tolerance (6 min walking distance test (6MWD)),
dyspnoea (Medical Research Council scale) and/or health
related quality of life (St George’s Respiratory
Questionnaire (SGRQ)).
Results: 51% of the patients reported at least one
chronic comorbidity added to COPD. Metabolic (systemic
hypertension, diabetes and/or dyslipidaemia) and heart
diseases (chronic heart failure and/or coronary heart
disease) were the most frequently reported comorbid
combinations (61% and 24%, respectively) among the
overall diseases associated with COPD. The prevalence of
patients with MCID was different across the comorbidity
categories and outcomes. In a multiple categorical logistic
regression model, the Charlson Index (OR 0.72 (96% CI
0.54 to 0.98) and 0.51 (96% CI 0.38 to 0.68) vs 6MWD
and SGRQ, respectively), metabolic diseases (OR 0.57
(96% CI 0.49 to 0.67) vs 6MWD) and heart diseases (OR
0.67 (96% CI 0.55 to 0.83) vs SGRQ) reduced the
probability to improve outcomes of rehabilitation.
Conclusions: Most patients with COPD undergoing
pulmonary rehabilitation have one or more comorbidities.
Despite the fact that the presence of comorbidities does
not preclude access to rehabilitation, the improvement in
exercise tolerance and quality of life after rehabilitation
may be reduced depending on the comorbidity.
Chronic obstructive pulmonary disease (COPD) is
one of the leading causes of morbidity and
mortality.1 2 Although alarming, this probably
underestimates the true burden of this disease on
health status, health care costs and overall
actual and projected prognoses.3 COPD is also an
important risk factor for other chronic diseases
that contribute to morbidity and mortality.4
Comorbidities are defined as other chronic
medical conditions that accompany a disease
process,5 and they are particularly prevalent in
the elderly.6–8 The most common chronic condi-
tions associated with COPD are hypertension,
diabetes, coronary artery disease, heart failure,
pulmonary infections, cancer and pulmonary
vascular disease.9–14 Comorbidities are an important
determinant of health related quality of life in
patients with COPD.13 15 16
Pulmonary rehabilitation is a non-pharmacological
comprehensive intervention, effective in the long
term management of symptomatic COPD of all
grades of severity,17 even in the elderly.18 Pulmonary
rehabilitation improves symptoms, quality of life and
exercise performance,19 and is effective in decreasing
consumption of health care resources.20
The aim of this study was to determine the
frequency and prevalence of chronic comorbidities
in patients with COPD and to assess their
influence on the effects of pulmonary rehabilita-
tion.
METHODS
Patients
Our study was approved by the our institutional
review board.
Of all the patients who were admitted to
hospital for rehabilitation purposes from January
2003 to December 2005 (n = 4055), we selected
2962 patients with COPD for retrospective analy-
sis. Patients were selected according to the follow-
ing criteria: primary diagnosis of (i) COPD (491
codes), as defined and classified according to the
Global Initiative for Chronic Obstructive Lung
Disease (GOLD) guidelines19 and/or (ii) pulmonary
emphysema (492 code) and (iii) respiratory failure
(518.86 codes). Spirometric severity of COPD was
established according to the GOLD guidelines.21
Therefore, patients with asthma or any other
pulmonary diseases (either obstructive or restric-
tive) were excluded from the study. Discharge
diagnosis was made by a physician specialising in
pulmonary medicine. The diagnosis of each patient
was recorded on an electronic database according
to the codes of the International Classification of
Diseases, version 9-CM.22
Comorbidities
Comorbid conditions were diagnosed according to
the International Classification of Health Problems
in Primary Care23 and retrieved from the medical
files. All patients were grouped according to the
following comorbidity categories: 0 (absence of
Chronic obstructive pulmonary disease
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associated chronic conditions), 1 and >2 (depending on the
relative number of associated chronic conditions).
The frequency (as a percentage of the total) of each chronic
disease and combined diseases—heart disease (chronic heart
failure, coronary heart disease), metabolic disease (systemic
hypertension, diabetes, dyslipidaemia, namely metabolic syn-
drome), skeletal disease (osteoporosis, arthrosis) and other
disease1–3—among the total amount of comorbidities was
established. The prevalence of the same single or combined
comorbidities was also calculated taking the whole cohort of
COPD into account.
Individuals’ self-reported comorbidities, as assessed by the
Charlson Index,24 which assigns to each disease a score that is
proportional to the disease related risk of death, was also
retrieved by these files. The Charlson Index was computed
during the hospital stay by the physician in charge of each
admitted patient. The computed Charlson Index was not
adjusted for age and did not include COPD in the individual’s
score, as previously suggested.25
Pulmonary rehabilitation
Patients were selected for pulmonary rehabilitation according to
the British Thoracic Society statement17 and were treated as
inpatients or outpatients, depending on relative indications,
preference and the individual’s loss of functional limitations
other than those related to the lung. Most patients were directly
transferred from acute care hospitals. Daily sessions—up to a
minimum of 15— including peripheral and/or respiratory
muscle training were conducted as previously reported.26 27
Pulmonary rehabilitation outcomes
The prevalence of patients with a positive response to
pulmonary rehabilitation, corresponding to the minimum
clinically important difference (MCID) of each outcome, was
calculated in terms of three major measures28–30: exercise
tolerance (+54 m in the 6 min walking distance test
(6MWD)),31 breathlessness (21 point on the 1–5 point modified
Medical Research Council (MRC) scale)32 and quality of life (24
points on the St George’s Respiratory Questionnaire (SGRQ)).33
The percentage of patients who withdrew from pulmonary
rehabilitation was also recorded in the study cohort.
Statistics
Analyses were carried out using SPSS software (SPSS 8.0 for
Windows; SPSS, Chicago, Illinois, USA). Qualitative variables
are expressed as percentages; quantitative variables are
expressed as means (SD). Comparison of categorical variables
among comorbidity categories was made using the x2 test.
Correlations between rehabilitation outcomes (MRC,
6MWD, SGRQ) and categorical variables in the study were
first analysed with the univariate method (for details see the
online supplement material). The multivariate logistic regres-
sion model was then applied to define the predictive role of
comorbidities and other potential confounders when related to
the outcomes of the rehabilitation program (for details see the
online supplement material).
All results were considered to be statistically significant at
p,0.05.
RESULTS
Patients with COPD treated during the study period and
included in this analysis (n = 2962) were 73% of all those
respiratory patients who attended the pulmonary rehabilitation
programme in our centre between January 2003 and December
2005. The main anthropometric and clinical characteristics of
the patients are reported in table 1. Most patients were male
(73%) with moderate to severe COPD and a disability grade
(mean 6MWD, MRC and SGRQ values) that led to elective
indications for rehabilitation. Patients with very severe COPD
who were on long term oxygen therapy represented approxi-
mately 9% of the total cohort.
Fifty-one per cent (1519 patients) of the cohort reported at
least one comorbidity (38%, 11% and 2% for comorbidity
categories 1, 2 and.2, respectively). Distribution of staging and
functional status was no different across the categories.
Figure 1A shows the frequency distribution (% of total) of the
main chronic diseases in those patients with COPD who had at
least one comorbidity. The six most frequent diseases repre-
sented .85% of the total number of comorbidities. Other, less
frequently reported, comorbidities were atherosclerosis (2%),
cancer (1%) and dementia (1%), and liver (2%), renal (3%),
stomach (1%) and intestinal (1%) diseases. The frequency
distribution (% of total) of the comorbidity combinations is
Table 1 Anthropometric, demographic and functional characteristics of the study cohort
All patients
Comorbidity categories
p Value0 1 >2
n 2962 1443 1138 381
Age (y) 71.1 (8.0) 70.9 (8.3) 71.3 (7.6) 71.3 (7.7) 0.429
Sex (M/F) (n (%)) 2150/812
(72/28)
1060/383
(73/27)
816/322
(71/29)
274/107
(72/28)
0.188
Charlson Index 1.52 (0.72) 1.25 (0.56) 1.79 (0.78) 2.76 (0.68) 0.001
FEV1 (% predicted) 49.3 (14.8) 48.8 (14.9) 50.0 (14.5) 49.5 (15.4) 0.128
ATS-ERS* staging (n (%))
Mild 2 (0.0) 0 (0.0) 2 (0.1) 0 (0.0)
Moderate 1400 (47.2) 648 (44.9) 571 (50.1) 181 (47.5)
Severe 1251 (42.2) 640 (44.3) 451 (39.6) 160 (41.9)
Very severe 309 (10.4) 155 (10.7) 114 (10.0) 40 (10.4)
6MWD (baseline) (m) 335.2 (95.6) 333.5 (96.2) 344.2 (93.1) 313.8 (98.4) 0.001
MRC grade (baseline) 3.7 (0.92) 3.7 (0.91) 3.6 (0.91) 3.9 (0.96) 0.030
SGRQ total score (baseline) 39.5 (16.4) 40.5 (16.8) 39.8 (17.0) 36.3 (12.9) 0.414
Data are mean (SD).
*Mild COPD is defined as FEV1/FVC ratio(0.7 and FEV1%>80; moderate COPD as FEV1/FVC ratio(0.7 and FEV1% 50–80; severe
COPD as FEV1/FVC ratio(0.7 and FEV1% 30–50; and very severe COPD FEV1/FVC ratio(0.7 and FEV1% ,30.
6MWD, 6 min walking distance test; FEV1, forced expiratory volume in 1 s; MRC, Medical Research Council dyspnoea score;
SGRQ, St. George’s Respiratory Questionnaire total score.
Chronic obstructive pulmonary disease
488 Thorax 2008;63:487–492. doi:10.1136/thx.2007.086371
 on 29 May 2008 thorax.bmj.comDownloaded from 
shown in fig 1B. Heart disease (24%), metabolic disease (62%)
and skeletal disease (7%) were the most frequently reported.
Taking the whole cohort of COPD into account, systemic
arterial hypertension was the most prevalent comorbidity
(27.4%), followed by chronic heart failure (10.5%) and diabetes
(10.3%), whereas the prevalence of combined heart disease,
metabolic disease and skeletal disease was 16%, 38% and 5%,
respectively (figure not displayed).
Mean changes after pulmonary rehabilitation were 67 (SD
47) m in the 6MWD,21.1 (SD 0.7) for the MRC score and26.4
(SD 4.5) for the SGRQ score. However, the number and per cent
of patients with MCID in the MRC score and SGRQ score (but
not in the 6MWD) were different (p,0.05) across the
comorbidity categories (table 2). Withdrawal rate from
pulmonary rehabilitation (3%) was no different across the same
categories (table 2).
Univariate analysis for binary variables showed that age (with
SGRQ, p = 0.001), Charlson Index (with 6MWD and SGRQ,
p = 0.001), forced expiratory volume in 1 s (FEV1) (with MRC,
p = 0.032), heart disease (with 6MWD and SGRQ, p = 0.001),
metabolic disease (with 6MWD, p = 0.001; MRC, p = 0.004;
SGRQ, p = 0.043) and skeletal disease (with MRC, p = 0.049)
were significantly related to outcome and were then entered
into the multivariate analysis (for detailed statistics, see also the
table in the online supplement material).
Table 3 displays the results of the multiple logistic regression
analysis. Age, FEV1, Charlson Index, and heart disease and
metabolic disease combinations entered the prediction equation
as independent variables. In particular, airway obstruction
significantly predicted the improvement in MRC score;
Charlson Index and metabolic disease were inversely related
to improvement in 6MWD; and heart disease directly and
indirectly predicted the improvement in 6MWD and SGRQ,
respectively.
The overall results did not change when taking the subgroups
of patients with COPD undergoing inpatient and outpatient
(13% of total) rehabilitation.
DISCUSSION
Our study showed that most patients with COPD undergoing
pulmonary rehabilitation have one or more chronic comorbid-
ities and that the severity of comorbidities, particularly the
simultaneous presence of metabolic and/or heart diseases,
significantly reduces the beneficial effects of pulmonary
rehabilitation on exercise tolerance and perceived quality of life.
Complex chronic comorbidities may significantly affect the
clinical severity of COPD,7 11 18 32 being present in up to 56% of
patients with COPD compared with non-COPD subjects of the
same age.32 The prevalence of chronic comorbidities varies
among studies.9 25 Although the methodology was similar, the
prevalence of at least one comorbidity in our cohort was lower
(approximately 65%) than the prevalence reported in other
studies (.70%).34 35 Indeed, the population we examined was
selected because it included only patients referred for pulmon-
ary rehabilitation. The prevalence of comorbidities in patients
with COPD referred for pulmonary rehabilitation has not been
definitively examined previously,36 37 probably because of the
relatively low number of patients and inclusion/exclusion
criteria of pulmonary rehabilitation. Most (.90%) patients
included in our study had moderate to severe COPD (stages 2
and 3 according to the GOLD guidelines), suggesting that
patients with very severe (stage 4) COPD, possibly with more
and more severe chronic comorbidities,6 38 are less frequently
referred for rehabilitation. Interestingly, the reported comorbid-
ity Charlson score24 39 in our patients was similar (1.26–2.85) to
that reported in other studies.36 40 41
Table 2 Patients with a predefined positive response (MCID) to pulmonary rehabilitation in terms of
improvement in exercise tolerance, dyspnoea and quality of life
All patients
(n = 2962)
Comorbidity categories
x20 (n = 1443) 1 (n = 1136) >2 (n = 383)
6MWD +54 m (n (%)) 1822 (61.5) 904 (62.6) 680 (59.8) 238 (62.4) 0.298
MRC grade 21 (n (%)) 2416 (81.5) 1170 (81.0) 914 (80.3) 332 (87.1) 0.010
SGRQ total 24 (n (%)) 1845 (62.2) 962 (66.6) 658 (57.9) 225 (59.0) 0.001
Withdrawal rate (%) 2.82 1.89 3.44 1.26 0.561
Data are presented as mean (SD).
6MWD, 6 min walking distance test; MCID, minimum clinically important difference; MRC, Medical Research Council dyspnoea
score; SGRQ, St. George’s Respiratory Questionnaire total score.
Figure 1 Frequency distribution (% of total) of individual chronic
comorbidities (A) and combinations of comorbidities (B) added to
chronic obstructive pulmonary disease (COPD) in the population. CHF,
chronic heart failure.
Chronic obstructive pulmonary disease
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Systemic hypertension, chronic heart failure, diabetes, cor-
onary heart disease, dyslipidaemia and osteoporosis–arthrosis
ranked as the six most frequent among all reported comorbid-
ities; these six represented .85% altogether (fig 1A), and their
proportions were similar to those reported in previous studies.37
The same features were also observed with regard to the
prevalence of these diseases within the cohort of studied COPD
(see also results).
Metabolic disease and heart disease were the two most frequent
disease combinations among all reported comorbidities (fig 1B). It
is noteworthy that the term metabolic disease only approximates
the internationally shared definition of ‘‘metabolic syndrome’’.42
Notwithstanding, metabolic alterations together with chronic
heart diseases are well known to independently worsen the
prognosis of adults.1–3 In elderly patients with complex comorbid-
ities, obesity and low physical activity are factors that increase the
risk of death by 15% and 3%, respectively.3 Both of these factors
are important determinants of survival in patients with
COPD36 43 44 and are likely to be improved with comprehensive
rehabilitation.17 Therefore, it is not surprising to find this frequent
pattern of comorbidities in patients with COPD enrolled in
pulmonary rehabilitation programmes.
Exercise performance, dyspnoea and quality of life (as
assessed by the SGRQ) are widely recognised as important
patient centred outcomes of COPD, whose favourable change
indicates the clinical effect of treatment,21 particularly pulmon-
ary rehabilitation.45 The MCID method adopted here to define
the a priori criteria for outcome improvement seems appropriate
in this field.29 The proportion of patients with significant
changes in MRC (higher percentage in category >2) and SGRQ
(higher percentage in category 0) was different across the
comorbidity categories (table 2). However, the magnitude of
their change after rehabilitation was similar in these groups,
confirming the ability of pulmonary rehabilitation to individu-
ally target (whenever possible) the reasonably reachable goals
for reducing disability.
The proportion of patients who reported a positive change in
all three pulmonary rehabilitation outcomes in our study was
.50%. Overall, this percentage was higher than that in a
previous study29 in outpatients with COPD. These differences
may be partially explained by the different site (inpatient
facility for most of our patients with COPD) and grade of
physical disability (mean 285 vs 335 m for the 6MWD in De
Torres and colleagues29 and in our study, respectively) recorded
at baseline.
To our knowledge, our study is the first to investigate the
predictive role of comorbidities on the effect of pulmonary
rehabilitation. To date, this information is still lacking in the
field of rehabilitation with regard to patients with COPD. Only
one study38 has considered the independent role of comorbidities
on functional outcomes (balance and gait) after physical
intervention in over 700 elderly patients who were recovering
from stroke or who had Parkinson’s disease or osteoarthritis.
The investigators observed that the determinants of poor
recovery were characterised by the combination of ‘‘more
disabling diseases’’ (COPD, heart failure, peripheral artery
disease, diabetes and cancer) rather than the effect of each
chronic disease, independent of age, cognitive status or
functional status at admission.
Our findings are consistent with those of De Fazio and
colleagues38; indeed, we have shown that the combinations of
chronic comorbidities (metabolic and/or heart diseases), but not
each chronic disease per se associated with COPD, indepen-
dently predict improvement after pulmonary rehabilitation
(table 3). In addition, the overall impact of comorbidities (here
quantified by means of the Charlson Index) inversely predicts
the improvement of both exercise tolerance and quality of life
after rehabilitation. This suggests that the more complex cases
are those less likely to benefit from pulmonary rehabilitation.
The presence of associated metabolic disorders is inversely
related to improvement in 6MWD. Indeed, it is likely that the
systemic complications associated with hypertension, diabetes,
dyslipidaemia and overweight limit the ability to improve
physical performance in terms of exercise tolerance, as known in
humans.46
Interestingly, the presence of combined heart diseases acts as
both positive and negative predictors depending on the outcome
investigated. In particular, it directly relates to the improvement
in 6MWD but inversely relates to the change in quality of life
(SGRQ).
Despite the large contribution that cardiac dysfunction may
give per se to health status and prognosis in adults,47 training
during rehabilitation in these chronic diseases appears to be
recommended.48 These diseases, even if associated with COPD,
are not likely to alter the individual’s ability to improve his or
her physical performance. On the other hand, the combination
with chronic heart diseases (but not of the metabolic disorders)
inversely predicts the effect of pulmonary rehabilitation on the
quality of life of patients with COPD. We can only speculate
that this particular interaction and disease complexity may
negatively impact on the potential benefit of rehabilitation on
the individual’s perceived health status, as reported previously.49
Thus on the one hand the presence of more complex
comorbidities among patients with COPD undergoing
Table 3 Factors predicting pulmonary rehabilitation outcome in the cohort of patients with COPD
Dependent variable Variable b SE Exp (b) OR 96% CI p Value
6MWD improvement Charlson Index 20.31 0.14 0.72 0.54 to 0.98 0.024
Heart disease 0.86 0.11 2.36 1.85 to 3.01 0.001
Metabolic disease 20.55 0.07 0.57 0.49 to 0.67 0.001
MRC improvement FEV1 0.53 0.13 1.71 1.34 to 2.40 0.001
Metabolic disease 0.16 0.09 1.17 0.93 to 1.77 0.104
Skeletal disease 20.36 0.20 0.69 0.66 to 1.48 0.074
SGRQ Improvement Age 0.30 0.07 1.35 1.15 to 1.59 0.001
Charlson Index 20.66 0.14 0.51 0.38 to 0.68 0.001
Heart disease 20.38 0.10 0.67 0.55 to 0.83 0.001
Metabolic disease 20.09 0.07 0.91 0.77 to 1.07 0.249
For details of the included variables, see the results section.
6MWD, 6 min walking distance test; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; MRC,
Medical Research Council dyspnoea score; SGRQ, St George’s Respiratory Questionnaire total score.
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pulmonary rehabilitation does not necessarily mean that this
process is likely to benefit those patients less. On the other
hand, however, it probably implies that outcomes should be
better targeted and intervention should be better tailored to
take account of this factor. Interestingly, despite the fact that
rehabilitation in our cohort of COPD was delivered in two
different setting (13% as outpatients), the overall results were
similar in these subgroups of patients, confirming a quite
homogeneous cohort and making the clinical message even
stronger.
Despite our new and original findings, our study has
limitations which need to be addressed. Firstly, this is a
retrospective cohort analysis and hence a further prospective
trial is needed to confirm the results. Secondly, the pattern of
comorbidities in our single centre COPD cohort, although
consistent, should be confirmed in a multicentre study where
objective confirmation on the single diagnosis is also considered.
Thirdly, diagnosis of the comorbidities was based on a self-
reported method; therefore, the predictive role of the metabolic
and heart diseases on the effects of pulmonary rehabilitation
need to be corroborated by more precise biological or
pathogenetic indicators. Fourthly, other potential individual
factors such as socioeconomic status, smoking habit and pack
years were not retrospectively available nor were they taken
into account as potential confounders in the predictive analysis.
Notwithstanding these important factors which limit the
generalisability of this study by using a single site, our findings
underline the necessity to globally assess patients with COPD
for their functions and comorbidities in order to determine the
most appropriate approach for treating them.50
In conclusion, this study shows that chronic comorbidities
are very frequent in patients with COPD undergoing rehabilita-
tion but a positive effect is reached in .50% of patients.
Comorbidity risk score and the combinations of both heart and
metabolic diseases, in particular, independently predict the
effect of pulmonary rehabilitation on exercise capacity and
quality of life.
In the context of the current evidence and taking the
limitations into account, our findings enable physicians to
carefully investigate the impact of comorbidities as potential
predictors and confounders in the population of patients with
COPD enrolled in rehabilitation programmes.
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Progressive dyspnoea, pleural
effusions and lytic bone lesions
CLINICAL PRESENTATION
A 72-year-old man was referred following a CT scan which
showed lytic and sclerotic lesions in the spine and pelvis with
bilateral pleural effusions and thickening. The patient was an
ex-smoker with progressive dyspnoea and significant weight
loss over 1 year. There was no history of exposure to asbestos.
Pleural fluid analysis revealed a transudate with no malignant
cells. A repeat CT scan showed small bilateral pleural effusions
and rinds of solid tissue within the pleural space extending to
surround the descending thoracic aorta and aortic arch. Nodular
reticular shadowing was seen in both lungs extending to the
periphery, particularly in the upper lobes. Another soft tissue
rind surrounded the kidneys with renal sinus fat obliteration.
Presumed metastases were seen in both iliac bones with
surrounding sclerosis on the left and the T7 vertebral body.
An isotope bone scan revealed extensive focal increased tracer
activity in lower limb long bones (fig 1). Initial pleural biopsy,
performed to investigate the diagnosis of malignancy, showed
non-specific fibrosis. Before further investigations could be
undertaken, the patient died from aspiration pneumonia
following a stroke. Because of the suspicion of mesothelioma,
a coronial autopsy was undertaken which confirmed bilateral
pleural thickening up to 1 cm with focal calcification but no
macroscopic parenchymal infiltration.
QUESTION
What is the diagnosis?
See page 554
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